An Integrated Research Program In Clincial Toxicology Toxicovigilance And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
Drug-related deaths in Australia account for 6.6% of all deaths (ABS 2009). In much of the rural Asia-Pacific, pesticide poisoning and snakebite are major problems. This research supports an integrated national and international clinical toxicology research program covering medicine and chemical poisoning, serious adverse drug reactions, snake and spider bite. Its focus is on the applied research needed to detect new problems and rapidly translate early findings into better treatment, regulation ....Drug-related deaths in Australia account for 6.6% of all deaths (ABS 2009). In much of the rural Asia-Pacific, pesticide poisoning and snakebite are major problems. This research supports an integrated national and international clinical toxicology research program covering medicine and chemical poisoning, serious adverse drug reactions, snake and spider bite. Its focus is on the applied research needed to detect new problems and rapidly translate early findings into better treatment, regulations & policy.Read moreRead less
Development Of Systemic Therapies To Improve Response And Prevent Resistance In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
This program of research utilises the unique resources at Melanoma Institute Australia (MIA) to understand the biology of prolonged response and resistance to novel drug therapies used in metastatic melanoma, a cancer that now leads the field in the discovery of new targets for therapeutic manipulation. This program also aims to create new methods to efficiently test and develop drug therapy combinations in humans to improve patient outcomes further or prevent metastatic melanoma altogether.
Major advances in cancer treatment has been made by identifying gene mutations in cancers to which the cancer is “addicted”, such that turning off the effects of the mutations leads to death of the cancer cells. Grant McArthur has been successful in applying this principle to rare types of sarcoma bringing his work to routine clinical practice globally. In this application he will investigate targeting the BRAF, KIT and MYC genes focusing on melanoma, a major cancer problem in Australia.
This Practitioner Fellowship will support studies that will contribute directly to the efforts to eliminate HCV infection from Australia. The research program aims to reduce transmission of HCV infection by evaluating the best models of care for i) engaging and treating high risk individuals with HCV infection, including people who inject drugs and prisoners, ii) preventing reinfection with HCV, and iii) re-treatment of individuals who fail treatment due to drug resistance.